ISU Abxis (A086890) Stock Overview
A biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A086890 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ISU Abxis Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,895.00 |
| 52 Week High | ₩6,480.00 |
| 52 Week Low | ₩3,945.00 |
| Beta | 0.50 |
| 1 Month Change | -7.64% |
| 3 Month Change | -4.58% |
| 1 Year Change | -17.45% |
| 3 Year Change | -16.47% |
| 5 Year Change | -29.57% |
| Change since IPO | -46.79% |
Recent News & Updates
ISU Abxis Co., Ltd. (KOSDAQ:086890) Held Back By Insufficient Growth Even After Shares Climb 26%
Feb 27
Why Investors Shouldn't Be Surprised By ISU Abxis Co., Ltd.'s (KOSDAQ:086890) 26% Share Price Plunge
Nov 14ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Nov 12ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price
Aug 07ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Jun 10Recent updates
ISU Abxis Co., Ltd. (KOSDAQ:086890) Held Back By Insufficient Growth Even After Shares Climb 26%
Feb 27Why Investors Shouldn't Be Surprised By ISU Abxis Co., Ltd.'s (KOSDAQ:086890) 26% Share Price Plunge
Nov 14ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Nov 12ISU Abxis Co., Ltd.'s (KOSDAQ:086890) Intrinsic Value Is Potentially 84% Above Its Share Price
Aug 07ISU Abxis (KOSDAQ:086890) Takes On Some Risk With Its Use Of Debt
Jun 10Benign Growth For ISU Abxis Co., Ltd. (KOSDAQ:086890) Underpins Its Share Price
Mar 12We Think ISU Abxis (KOSDAQ:086890) Has A Fair Chunk Of Debt
Feb 17
ISU Abxis'(KOSDAQ:086890) Share Price Is Down 21% Over The Past Three Years.
Dec 25Shareholder Returns
| A086890 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.7% | 5.9% | 4.0% |
| 1Y | -17.5% | 27.1% | 56.8% |
Return vs Industry: A086890 underperformed the KR Biotechs industry which returned 27.1% over the past year.
Return vs Market: A086890 underperformed the KR Market which returned 56.8% over the past year.
Price Volatility
| A086890 volatility | |
|---|---|
| A086890 Average Weekly Movement | 3.9% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in KR Market | 10.4% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A086890 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A086890's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 178 | Ryu Soo | www.abxis.com |
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications; Febulein, a sodium phenylbutyrate granule for the treatment of urea dystrophy; and Trientop, a trientine hydrochloride capsule for the treatment of Wilson’s disease. It develops ISU104 for head, neck, colorectal, and breast cancer; ISU104 CAR-NK for leukemia and solid tumors; ABX2001 for solid tumors; ISU304 for hemophilia B; ISU305 for paroxysmal nocturnal hemoglobinuria and other autoimmune diseases; and ISU203 for dementia caused by Alzheimer’s disease.
ISU Abxis Co., Ltd. Fundamentals Summary
| A086890 fundamental statistics | |
|---|---|
| Market cap | ₩194.17b |
| Earnings (TTM) | ₩29.52b |
| Revenue (TTM) | ₩59.42b |
Is A086890 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A086890 income statement (TTM) | |
|---|---|
| Revenue | ₩59.42b |
| Cost of Revenue | ₩18.16b |
| Gross Profit | ₩41.25b |
| Other Expenses | ₩11.73b |
| Earnings | ₩29.52b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 744.20 |
| Gross Margin | 69.43% |
| Net Profit Margin | 49.68% |
| Debt/Equity Ratio | 24.8% |
How did A086890 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/02 05:48 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ISU Abxis Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Song-hyup Han | Daishin Securities Co. Ltd. |
| Byung Hwa Han | Eugene Investment & Securities Co Ltd. |
| Jung-In Lee | Korea Investment & Securities Co., Ltd. |